Median Technologies Aims to Expand Lung Cancer Screening Tool After FDA Clearance

Event summary

  • Median Technologies will showcase its AI-powered lung cancer screening software, eyonis® LCS, at the European Congress of Radiology (ECR) 2026 in Vienna from March 4–6.
  • eyonis® LCS received FDA 510(k) clearance in February 2026, achieving 93.3% sensitivity, 92.4% specificity, and 99.9% negative predictive value in detecting lung cancer in low-dose CT scans.
  • The company anticipates obtaining CE marking for eyonis® LCS in Q2 2026, paving the way for broader European market entry.
  • Median will host multiple presentations at ECR, including sessions on AI-assisted lung nodule risk assessment and the transformation of lung cancer screening through AI.

The big picture

Median Technologies is advancing its AI-powered lung cancer screening tool, eyonis® LCS, following FDA clearance and ahead of anticipated CE marking. The company’s participation in the European Congress of Radiology underscores its push to integrate AI into clinical practice, aligning with broader industry trends toward early cancer detection and regulatory validation of AI-driven medical devices. The success of eyonis® LCS could influence the adoption of similar AI tools in oncology screening.

What we're watching

Regulatory Pathway
Whether Median can secure CE marking for eyonis® LCS in Q2 2026, enabling its entry into the European market.
Market Adoption
The pace at which clinicians and healthcare systems integrate AI-powered tools like eyonis® LCS into lung cancer screening programs.
Competitive Dynamics
How Median’s FDA-cleared and soon-to-be CE-marked software positions it against other AI-driven diagnostic tools in the lung cancer screening space.